Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer
FDA granted accelerated approval to Mirati’s KRAS drug adagrasib, which will be marketed as Krazati. The green light comes two days ahead of the expected decision and cements the biotech as the second in the KRAS field behind leader Amgen, maker of the May 2021-approved Lumakras.
The nod is for second-line treatment for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.